 |
185 Diseases |  |
81 Trials |
|
81 Trials |  |
6476 News |  |
| «12...2122232425262728293031...8182» |
- phenobarbital / Generic mfg., levetiracetam / Generic mfg.
EEG and Clinical Characteristics of Parechovirus Encephalitis: an Under-recognized Neonatal Encephalitis (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1255;
CSF indices were normal in all patients. EEG was abnormal in all patients where performed (n=7).
- levetiracetam / Generic mfg., carbamazepine / Generic mfg.
Effects of Anti-seizure Medication Exposure on Pcos-like Symptoms in Women with Epilepsy (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1252;
We used Student’s t-test for continuous variables of equal variances, chi-square test for categorical variables, and Fisher’s exact test for categorical variables with frequencies of less than 5. Significance was set at p< 0.05.
- Fycompa (perampanel) / Eisai, Aptiom (eslicarbazepine) / Sumitomo Dainippon, BIAL
Practice Trends in Women with Epilepsy (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1220;
Based on available data, several organizations including the AAN (American Academy of Neurology) and the AES (American Epilepsy Society) recommend avoidance of valproate use in women of child bearing age group due to substantial risk of major congenital malformations and adverse neuro-cognitive outcomes and recommend use of folic acid supplementation. However, our study finds that there is a practice gap between recommendations and clinician practice trends illustrating the need for more clinician education and need for involvement of epileptologists in the care of these patients to ensure best outcomes.
- Fycompa (perampanel) / Eisai
Efficacy and Safety of Perampanel as First or Only Adjunctive Therapy in Patients with Focal-onset Seizures (FOS) or Generalized Tonic-clonic Seizures (GTCS) in Studies 412, 501, 410, and 509 (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1195;
P, P=N/A,
Based on the available data from these studies, perampanel as a first or only adjunctive ASM was found to be efficacious and generally well tolerated. These data support the use of perampanel as an early-line treatment option for patients with various seizure types (FOS, FBTCS, and GTCS).
- The Effects of Anti-seizure Medications on Lipid Values in Adults Considering Ketogenic Diet Therapy (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1167;
However, there was a significant difference between ASM groups in the frequency of participants with dyslipidemia. There was a significant difference in the frequency of patients with high cholesterol level (TC > 200) among the four ASM groups (χ2(3) = 9.418, p = 0.024).
- levetiracetam / Generic mfg.
Seizures Characteristics of Individuals with Succinic Semialdehyde Dehydrogenase Deficiency: Results from a Multinational Longitudinal Study (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1152;
By correlations of neurophysiological, genetic, and biochemical data with the clinical outcomes, we have found the protective factors which are associated with epilepsy being better controlled. Additionally, by elucidating the details related to the timing of the decline of GABA and GHB levels in correlation with seizure onset, we have added information that further advances the efforts of developing novel therapeutic approaches for individuals with SSADHD.
- Xcopri (cenobamate) / SK Bio, Angelini Group, Endo
Effect of Anti-seizure Medication on Seizure-induced Brain Activation (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1143;
While LEV displayed reduced protection against MES seizures compared to CBM and PHT, no differences in cFOS immunoreactivity were seen between the ASMs suggesting that these ASMs provide little protection against activation of these brain regions during an MES seizure, and may indicate that CBT and PHT block seizures downstream of brain activation. All ASMs in the 6 Hz test displayed complete protection, but differences in cFOS levels between ASMs and VEH were noted, suggesting that these ASMs provide protection against brain region activation during a 6 Hz seizure.
- Diastat (diazepam rectal gel) / Bausch Health, Nayzilam (midazolam intranasal) / UCB
Baseline Characteristics and Antiseizure Medication Use of Patients with Epilepsy in the Year Prior to Initiating Midazolam Nasal Spray, Diazepam Rectal Gel, or Diazepam Nasal Spray (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1133;
New users of MDZ-NS and DZP-NS showed generally similar baseline characteristics, but were older with more prior/concomitant ASMs vs the DZP-RG cohort. Baseline characteristics and prior/concomitant ASM use were influenced by approved patient age and BZP prescribing information, with adults most commonly receiving MDZ-NS.
- levetiracetam / Generic mfg., topiramate / Generic mfg., carbamazepine / Generic mfg.
Teratogenesis Risk Associated with Paired Antiseizure Medications in Pregnant Women with Epilepsy (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1129;
Pairings of ASMs can produce an additive effect on the FM rate. A notable exception is the pairing of LTG with VPA, TPM or CBZ which yields a reduction in FM hazard.
- levetiracetam / Generic mfg.
Reproductive Healthcare for People with Epilepsy: a Survey of Healthcare Providers (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1118;
Knowledge: Less than half of respondents are aware that only some antiseizure medications impact contraceptive efficacy (Table 1). About two-thirds to three-quarters of respondents believe that valproic acid is among ASMs with higher teratogenic risk and that levetiracetam is among ASMs with lower teratogenic risk.
- lacosamide / Generic mfg.
Outcomes of Patients on Lacosamide Medication During Pregnancy (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1102;
Additionally, DNCs exhibited a decreasing trend during pregnancy, confirming that regular, optimized LCM dosage changes may be necessary to achieve the best possible maternal and fetal outcomes. Future analyses in larger cohort sizes are needed.
- Outcome of Pregnancies Following Maternal Exposure to Antiepileptic Drugs: Experience of a Single Tertiary Referral Center in Lebanon (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1088;
Our study is the first to report pregnancy outcome in women with epilepsy in Lebanon and to report the initial data of the Lebanese registry affiliated to the EURAP. Drugs prescribed and dosages used did not induce any birth defects and overall outcome was favorable even though most women struggled to have access to medical care or have drug levels checked because of the economical and healthcare collapse of the country.
- levetiracetam / Generic mfg., brivaracetam / Generic mfg.
Brivaracetam Provides Better Neuroprotection Than Levetiracetam in the Treatment of Experimental Benzodiazepine-refractory Status Epilepticus (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1083;
This BRV-including combination was superior to the combination LEV (100 mg/kg) - midazolam (3 mg/kg) - ketamine (30 mg/kg) in that treatment paradigm. The BRV- including combination significantly reduced neuronal injury in 6 of 7 regions studied.
- felbamate / Generic mfg.
Efficacy of Felbamate in a Cohort of Patients with Epilepsy with Myoclonic Atonic Seizures (EMAS) (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1077;
There were 18 (67%) responders to felbamate, eight of whom (44% of responders) reported seizure freedom. The responder rate was much higher for felbamate than for levetiracetam (15%, p < 0.001) or valproic acid (32%, p = 0.001).
- levetiracetam / Generic mfg.
Treating for Two a Review of Anti Seizure Medication Changes and Seizure Frequency of Pregnant Patients in an Underserved Community (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1034;
However, we failed to reach statistical significance of our primary goals of comparing the states of seizure changes in anti seizure medications during pregnancy. Going forward, given that the data is categorical, we may explore further regression models with this data to best serve the pregnant patients with epilepsy in the state of New Mexico.
- Comparison of Antiseizure Medication Concentrations Measured Within and Outside a Central Laboratory (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1029;
Paired t-test was used to compare the concentration results between laboratories using R version 4.0.3. A p-value < 0.05 was considered statistically significant.
- Fycompa (perampanel) / Eisai
Study 512 Design: Perampanel as First Adjunctive Therapy in Patients Aged ≥ 12 Years with Focal-onset Seizures or Generalized Tonic-clonic Seizures Associated with Genetic Generalized Epilepsy (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1021;
P=N/A
A p-value < 0.05 was considered statistically significant. Study 512 will provide prospective, observational data on the real‑world use of perampanel as first adjunctive therapy in patients aged ≥ 12 years with epilepsy.
- Xcopri (cenobamate) / SK Bio, Angelini Group, Endo
The Pharmacokinetics of Cenobamate When Used as Monotherapy (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1009;
The following antiseizure medications (ASMs) were tested as covariates for statistically significant effects on the apparent clearance (CL/F) of cenobamate based on their use in the clinical studies of patients with focal seizures: carbamazepine, clobazam, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, topiramate, and valproate. Based on these findings, cenobamate monotherapy should result in plasma exposures comparable to those that have been demonstrated to be safe and effective when used as adjunctive therapy for the treatment of focal seizures.
- Fycompa (perampanel) / Eisai
Psychiatric and Behavioral Issues of Perampanel with Concomitant Levetiracetam in Pediatric Epilepsy (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1008;
The present results suggest that PER is well tolerated as an adjunctive therapy, including concomitant use with LEV. Further investigations to confirm this preliminary evidence are needed.
- VS-505 / Vidasym
Meta-analysis of Major Congenital Anomaly Outcomes Following Prenatal Exposure to Monotherapy Antiseizure Medications. (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1004;
Overall pooled data demonstrated that LTG and LEV exposure were associated with comparable MCA risks and tended to have a lower risk than CBZ and TPM exposures. Data were more limited in comparison to OXC exposure.
- levetiracetam / Generic mfg.
Beyond Epileptic Encephalopathies – Delineating the Mild End of the STXBP1 Spectrum (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_965;
The unifying clinical features of this spectrum include learning impairments to mild developmental delay only, and this clinical subset appears to be linked to a unique variant spectrum, where individuals with novel missense variants in STXBP1 can present with mild neurodevelopmental differences. These findings hint at previously undescribed functional consequences of novel variants on the STXBP1 protein and informs prognostic counseling of those with STXBP1-related disorder.
- levetiracetam / Generic mfg., brivaracetam / Generic mfg.
Real-world Outcomes in Patients on Concomitant Levetiracetam at Brivaracetam Initiation: Post Hoc Analysis by Levetiracetam Discontinuation Status () - Nov 29, 2022 - Abstract #AES2022AES_921;
The remaining 50% of patients who continued on a stable dose of LEV had a lower BRV retention than patients who discontinued LEV. In patients remaining on BRV for ≥12 months, the proportion of seizure-free patients was similar irrespective of LEV discontinuation status.
- Seizalam (midazolam intramuscular) / Pfizer
Time Is Brain: Improving Early Access to Antiseizure Medications During Status Epilepticus in the Pediatric Population () - Nov 29, 2022 - Abstract #AES2022AES_884;
After the survey, a simplified status algorithm adding IN midazolam and including levetiracetam as first line was created...After presenting the study by Chamberlain et al, 11% chose fosphenytoin and 89% levetiracetam... With the usage of a simplified algorithm and order set for medications, we hope to decrease the time to treat status epilepticus at our institution.
- levetiracetam / Generic mfg., clobazam / Generic mfg.
syngap1-related Disorder Genotype-phenotype Analysis Through Digital Registry () - Nov 29, 2022 - Abstract #AES2022AES_845;
Our retrospective analysis of database-derived medical records data regarding SYNGAP1-related disorder reveal an overall picture of developmental delay and ultimately intellectual disability as often the first diagnosis, followed by onset of epilepsy in the majority of individuals. These results can inform development of targeted clinical trial outcomes and highlight a window of opportunity for prevention or early identification of seizures between the diagnosis of developmental delay and the onset of epilepsy.
- phenobarbital / Generic mfg., levetiracetam / Generic mfg.
Early Discontinuation of Anti-seizure Medication in Neonates with Hypoxic-ischemic Encephalopathy Does Not Increase the Incidence of Seizures at 6 and 12 Months () - Nov 29, 2022 - Abstract #AES2022AES_835;
Phenobarbital and levetiracetam are common anti-seizure medications used in this population during the acute period. Early discontinuation of ASM after resolution of acute symptomatic seizures in neonates who underwent therapeutic hypothermia for HIE was not associated with increased seizure recurrence at 6 and 12 months of life compared to patients discharged home on ASM.
- levetiracetam / Generic mfg.
Disparities in the Utilization of Anti-seizure Medications in Critically Ill Patients Undergoing Continuous Electroencephalogram Monitoring () - Nov 29, 2022 - Abstract #AES2022AES_809;
While our data from three-center study did not show any apparent disparities in the prophylactic and therapeutic use of ASMs in clinical and electrographic ASyS and in the use of ASMs for EAs seen on cEEG, our study is limited by the sample size. Further research is needed to better understand disparities in ASMs management in this population in order to develop appropriate quality improvement interventions.
- levetiracetam / Generic mfg.
Adverse Effects of Levetiracetam in Newly Diagnosed and Treated Focal Epilepsy () - Nov 29, 2022 - Abstract #AES2022AES_802;
There were no significant differences in total AEP scores across ASMs. Patients with a baseline diagnosis of depression (adjusted marginal score ratio [aMSR]=1.25, 95% CI: 1.11-1.41, p< 0.001) or anxiety (aMSR=1.15, 95 % CI: 1.05-1.27, p=0.004) had significantly increased total AEP scores, irrespective of ASM use.
- Association of Prenatal Antiseizure Medication Exposure with Performance on Language and Mathematics Tests in Danish School-aged Children () - Nov 29, 2022 - Abstract #AES2022AES_766;
No statistically significant association were detected in children prenatally exposed to topiramate, gabapentin, and levetiracetam. The statistical power of these analyses was however limited, and findings should be interpreted with caution.
- Profile of Neuronal Apoptosis After Exposure to Voltage Gated Sodium Channel Blockers: Comparison Between Phenytoin, Lacosamide, Zonisamide, and Rufinamide () - Nov 29, 2022 - Abstract #AES2022AES_757;
Consistent with prior studies, we found that both phenobarbital and phenytoin significantly increased the number of degenerating cells in the hippocampus, nucleus accumbens, and lateral thalamus (P < 0.05). By contrast, rufinamide, zonisamide, and lacosamide were all without effect in all brain regions examined.
- Aptiom (eslicarbazepine) / Sumitomo Dainippon, BIAL
The Effect of Response to Eslicarbazepine Acetate (ESL) on Health-related Quality of Life (HRQoL) for Patients with Focal Seizures: A Post Hoc Analysis of a Phase IV Clinical Trial () - Nov 29, 2022 - Abstract #AES2022AES_721;
P4
ESL was either used as first adjunctive therapy with levetiracetam (LEV) or lamotrigine (LTG) with no history of other ASM therapy (Arm 1) or as later adjunctive therapy, following current or prior use of adjunctive therapy (Arm 2). Our post hoc analysis of the Phase IV trial suggests that response to ESL treatment as first adjunctive regimen to LEV or LTG resulted in improvement in patient’s HRQoL as measured by QOLIE-31.
- levetiracetam / Generic mfg.
Levetiracetam Reduces the Rate of Seizures and High-frequency Oscillations During the First Two Weeks After Lateral Fluid Percussion Injury: UCLA Data for the epibios4rx Project 2 Study () - Nov 29, 2022 - Abstract #AES2022AES_666;
One rat from each group had late seizures. The percentage of focal and generalized seizures was similar between the two groups.
- Aptiom (eslicarbazepine) / Sumitomo Dainippon, BIAL
Real World Evaluation of Serum Sodium Levels in Patients With Focal Seizures Treated With Eslicarbazepine Acetate () - Nov 29, 2022 - Abstract #AES2022AES_658;
The most common concomitant baseline ASMs were levetiracetam and lacosamide, and the most common comorbidities were bipolar disorder and chronic pulmonary disease. In both epilepsy and focal epilepsy groups, mean serum sodium values in patients treated with ESL aged ≥ 4 years did not change from baseline in a real-world clinical setting over a period of 12 months.
- ezogabine (XEN496) / Xenon
Assessing Prototype Antiseizure Medication Efficacy over Time in Lamotrigine-resistant Amygdala Kindled Rats () - Nov 29, 2022 - Abstract #AES2022AES_597;
ASM testing took place in fully kindled rats before and after testing several other (blinded) compounds (5-10) in the same cohort of animals (N=4-8). Efficacy (# protected from generalized seizure / N) was compared for each ASM (first and last test) by a Fisher’s exact test to determine significance (p < 0.05).
- Epilepsy in Haiti: Assessment, Treatment, and the Path Forward () - Nov 29, 2022 - Abstract #AES2022AES_596;
The patients had improved seizure control and reported few side effects. In addition, the rates of refractory epilepsy were lower than described in high-income countries.
- || Inavir (laninamivir) / Daiichi Sankyo
Review: Pharmacological management of seizures in patients with COVID-19: a systematic review. (Pubmed Central) - Nov 26, 2022
Standard guidelines for managing seizures in COVID-19 patients may be required. A limitation of this review is that it involved the use of case reports with no controls and a small number of patients.
- | levetiracetam / Generic mfg.
Preclinical, Journal: Caffeine impairs anticonvulsant effects of levetiracetam in the maximal electroshock seizure threshold test in mice. (Pubmed Central) - Nov 25, 2022
A limitation of this review is that it involved the use of case reports with no controls and a small number of patients. It is suggested that caffeine may negatively affect the anticonvulsant action of LEV in patients with epilepsy.
- | Journal: Thromboembolic Risks with Concurrent Direct Oral Anticoagulants and Antiseizure Medications: A Population-Based Analysis. (Pubmed Central) - Nov 25, 2022
Therefore, these antiseizure medication options among patients with epilepsy with concurrent DOAC should not be restricted solely based on their potential drug-drug interactions. Yet, the increased mortality during concurrent use of DOAC with phenytoin or valproate might call for caution.
- | phenobarbital / Generic mfg., levetiracetam / Generic mfg.
Retrospective data, Journal: Levetiracetam versus Phenobarbital for Neonatal Seizures: A Retrospective Cohort Study. (Pubmed Central) - Nov 20, 2022
Our study suggests a potential noninferiority and a more acceptable safety profile for LEV, which may thus be a reasonable option as first-line ASM for neonatal seizures in place of PB. Treatment should be initiated as early as possible since higher seizure frequencies predispose to less favorable responses.
- || phenytoin / Generic mfg., levetiracetam / Generic mfg.
Really fascinating slides thanks so much for sharing. Wish could hear your talk. Am increasingly convinced of the gut microbiome in Neuro protection also. Has Keppra been in any Neuro protection trials? Why were phenytoin and lamotrigine chosen? (Twitter) - Nov 20, 2022
- | levetiracetam / Generic mfg.
Journal: Suspected benzodiazepine withdrawal-associated seizures in 3 young dogs undergoing mechanical ventilation. (Pubmed Central) - Nov 19, 2022
Young dogs managed with benzodiazepines to facilitate MV may have acute onset of generalized seizures following cessation, which can be successfully managed with short-term benzodiazepine therapy. The 3 cases in this series demonstrated a positive outcome and were successfully managed following acute onset of generalized seizure activity post-MV.
- | levetiracetam / Generic mfg.
Journal: First-line levetiracetam versus enzyme-inducing antiseizure medication in glioma patients with epilepsy. (Pubmed Central) - Nov 19, 2022
The 3 cases in this series demonstrated a positive outcome and were successfully managed following acute onset of generalized seizure activity post-MV. In this study it was demonstrated that LEV had a significantly better effectiveness (i.e. less often ASM treatment failure for any reason or due to adverse effects) compared to EIASMs, supporting the current neuro-oncology guideline recommendations to avoid EIASMs in glioma patients.
- || levetiracetam / Generic mfg.
Review, Journal: The Association Between Alzheimer's Disease and Epilepsy: A Narrative Review. (Pubmed Central) - Nov 18, 2022
However, diagnosis of seizures in AD is complicated by the difficulty in identifying non-motor focal seizures in patients with cognitive decline, problems with obtaining histories, low sensitivity of standard scalp electroencephalogram (EEG) methods, nonspecific cerebrospinal fluid (CSF) and radiological findings. This article has reviewed and summarised the existing literature on the association between AD and epilepsy pertaining to epidemiology, pathophysiological links, risk factors, modalities for diagnosis, and treatment strategies.
- || phenobarbital / Generic mfg., levetiracetam / Generic mfg., midazolam hydrochloride / Generic mfg.
Review, Journal: Isolated ictal apnea in neonatal age: Clinical features and treatment options. A systematic review. (Pubmed Central) - Nov 18, 2022
This article has reviewed and summarised the existing literature on the association between AD and epilepsy pertaining to epidemiology, pathophysiological links, risk factors, modalities for diagnosis, and treatment strategies. Not homogeneous data and paucity of isolated IA currently reported in literature limits agreement about definition, management and treatment of entity, however an ever-growing attention is needed, and EEG/aEEG, despite their possible controversies in the diagnosis, should be performed to investigate unexplained forms of apnea.
- ||| levetiracetam / Generic mfg.
No, unfortunately not. Now to jerky seizure events. Keppra helps little. Pressured speech, stuttering more. I’m sorry you’re going through this. 🙏🏻 I wouldn’t wish it on anyone. So unsettling & disorienting. thinking follow up article. So many reaching out. Wish I could help more (Twitter) - Nov 18, 2022
- || Clinical, Observational data, Journal: A Multicenter, Cross-Sectional, Observational Study on Epilepsy and its Management Practices in India. (Pubmed Central) - Nov 16, 2022
No serious adverse drug reactions or new safety concerns were identified. Findings from this large, cross-sectional, observational, multicenter study indicate that first-generation AEDs sodium valproate and phenytoin continued to be used in a substantial number of patients on monotherapy and combination therapy in India, even though an increasing trend toward use of second-generation AEDs was noted in clinical practice.
- | levetiracetam / Generic mfg., carbamazepine / Generic mfg., oxcarbazepine / Generic mfg.
Journal: Association of HLA Alleles with Antiepileptic Drug-Induced Mild Cutaneous Reactions: A Case-Control Study of a Northeast Han Chinese Population. (Pubmed Central) - Nov 16, 2022
We failed to find statistically significant differences in HLA alleles between the cADRs group and the control group when considering all the drugs included in our study together or when considering oxcarbazepine (OXC), carbamazepine (CBZ), and levetiracetam (LEV) alone (P > 0.05). Our findings indicated that there was no correlation between HLA alleles and AED-induced mild cADRs in the Northeast Han Chinese population.
- | lamotrigine liquid oral suspension / OWP Pharma
Journal: An LC-ESI-MS/MS assay for the therapeutic drug monitoring of 15 anti-seizure medications in plasma of children with epilepsy. (Pubmed Central) - Nov 16, 2022
The precision and accuracy values for intra- and inter-assays were within ±15%. Consequently, the method was successfully implemented on pediatric patients undergoing mono- or polytherapy for epilepsy and provided timely concentration results to ordering clinicians.
- || levetiracetam / Generic mfg., oxcarbazepine / Generic mfg.
Retrospective data, Review, Journal, Monotherapy: Levetiracetam versus Oxcarbazepine as monotherapy in newly diagnosed focal epilepsy: A systematic review and meta-analysis. (Pubmed Central) - Nov 16, 2022
LEV is noninferior to OXC in terms of seizure freedom at week 24 and treatment withdrawal rate due to AEs among adults but long-term treatment data is still missing. Future multicentric double-blinded RCTs and real-world studies are of great need.
- | levetiracetam / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Preclinical, Journal: Levetiracetam Ameliorates Doxorubicin-Induced Chemobrain by Enhancing Cholinergic Transmission and Reducing Neuroinflammation Using an Experimental Rat Model and Molecular Docking Study. (Pubmed Central) - Nov 16, 2022
Analysis of the results suggested that administration of LEVE improved memory-related parameters in DOX-induced animals. The 'nootropic-like' activity could be related to diminished AChE and neuroinflammatory mediator levels.
- || levetiracetam / Generic mfg.
Review, Journal: Extreme late onset of genetic generalized epilepsy in older adults and the elderly: A cohort study and literature review. (Pubmed Central) - Nov 15, 2022
Valproate was used in only two patients and levetiracetam in 75% of them...They similarly had good seizure outcomes but a majority were on valproate. Our study shows that rarely, late-onset epilepsy can be GGE, which mostly has a good prognosis.